A Phase Ia/b study of MEK1/2 inhibitor binimetinib with MET inhibitor crizotinib in patients with RAS mutant advanced colorectal cancer (MErCuRIC) (BMC Cancer, 2025)

(untitled) - Aroldi, F; Elez, E; André, T; Perkins, G; Prenen, H; Popovici, V; Gallagher, P; Houlden, J; Collins, L; Roberts, C; Rolfo, C; Di Nicolantonio, F; et al.